Ex vivo use of cell-permeable succinate prodrug attenuates mitochondrial dysfunction in blood cells obtained from carbon monoxide-poisoned individuals
The purpose of this study was to evaluate a new pharmacological strategy using a first-generation succinate prodrug, NV118, in peripheral blood mononuclear cells (PBMCs) obtained from subjects with carbon monoxide (CO) poisoning and healthy controls. We obtained human blood cells from subjects with...
Saved in:
| Published in | American Journal of Physiology: Cell Physiology Vol. 319; no. 1; pp. C129 - C135 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Physiological Society
01.07.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0363-6143 1522-1563 1522-1563 |
| DOI | 10.1152/ajpcell.00539.2019 |
Cover
Loading…
| Abstract | The purpose of this study was to evaluate a new pharmacological strategy using a first-generation succinate prodrug, NV118, in peripheral blood mononuclear cells (PBMCs) obtained from subjects with carbon monoxide (CO) poisoning and healthy controls. We obtained human blood cells from subjects with CO poisoning and healthy control subjects. Intact PBMCs from subjects in the CO and Control group were analyzed with high-resolution respirometry measured in pmol O
2
per second per 10
−6
PBMCs. In addition to obtaining baseline respiration, NV118 (100 μM) was injected, and the same parameters of respiration were obtained for comparison in PBMCs. We measured mitochondrial dynamics with microscopy with the same conditions. We enrolled 37 patients (17 in the CO group and 20 in the Control group for comparison) in the study. PMBCs obtained from subjects in the CO group had overall significantly lower respiration compared with the Control group ( P < 0.0001). There was a significant increase in respiration with NV118, specifically with an increase in maximum respiration and respiration from complex II and complex IV ( P < 0.0001). The mitochondria in PBMCs demonstrated an overall increase in net movement compared with the Control group. Our results of this study suggest that the therapeutic compound, NV118, increases respiration at complex II and IV as well as restoration of mitochondrial movement in PBMCs obtained from subjects with CO poisoning. Mitochondrial-directed therapy offers a potential future strategy with further exploration in vivo. |
|---|---|
| AbstractList | The purpose of this study was to evaluate a new pharmacological strategy using a first generation succinate prodrug, NV118, in peripheral blood mononuclear cells (PBMCs) obtained from subjects with carbon monoxide (CO) poisoning and healthy controls. We obtained human blood cells from subjects with CO poisoning and healthy control subjects. Intact PBMCs from subjects in the CO and Control group were analyzed with high-resolution respirometry measured in pmol O
× s
× 10
PBMCs. In addition to obtaining baseline respiration, NV118 (250 mM) was injected and the same parameters of respiration were obtained for comparison in PBMCs. We measured mitochondrial dynamics with microscopy with the same conditions.
We enrolled 37 patients (17 in the CO group and 20 in the Control group for comparison) in the study. PMBCs obtained from subjects in the CO group had overall significantly lower respiration compared to the Control group (P < 0.0001). There was a significant increase in respiration with NV118, specifically with an increase in maximum respiration and respiration from Complex II and Complex IV (P < 0.0001). The mitochondria in PBMCs demonstrated an overall increase in net movement when compared to the Control group.
Our results of this study suggest that the therapeutic compound, NV118, increases respiration at Complex II and IV as well as restoration of mitochondrial movement in PBMCs obtained from subjects with CO poisoning. Mitochondrial-directed therapy offers a potential future strategy with further exploration in vivo. The purpose of this study was to evaluate a new pharmacological strategy using a first-generation succinate prodrug, NV118, in peripheral blood mononuclear cells (PBMCs) obtained from subjects with carbon monoxide (CO) poisoning and healthy controls. We obtained human blood cells from subjects with CO poisoning and healthy control subjects. Intact PBMCs from subjects in the CO and Control group were analyzed with high-resolution respirometry measured in pmol O 2 per second per 10 −6 PBMCs. In addition to obtaining baseline respiration, NV118 (100 μM) was injected, and the same parameters of respiration were obtained for comparison in PBMCs. We measured mitochondrial dynamics with microscopy with the same conditions. We enrolled 37 patients (17 in the CO group and 20 in the Control group for comparison) in the study. PMBCs obtained from subjects in the CO group had overall significantly lower respiration compared with the Control group ( P < 0.0001). There was a significant increase in respiration with NV118, specifically with an increase in maximum respiration and respiration from complex II and complex IV ( P < 0.0001). The mitochondria in PBMCs demonstrated an overall increase in net movement compared with the Control group. Our results of this study suggest that the therapeutic compound, NV118, increases respiration at complex II and IV as well as restoration of mitochondrial movement in PBMCs obtained from subjects with CO poisoning. Mitochondrial-directed therapy offers a potential future strategy with further exploration in vivo. The purpose of this study was to evaluate a new pharmacological strategy using a first-generation succinate prodrug, NV118, in peripheral blood mononuclear cells (PBMCs) obtained from subjects with carbon monoxide (CO) poisoning and healthy controls. We obtained human blood cells from subjects with CO poisoning and healthy control subjects. Intact PBMCs from subjects in the CO and Control group were analyzed with high-resolution respirometry measured in pmol O2 per second per 10-6 PBMCs. In addition to obtaining baseline respiration, NV118 (100 μM) was injected, and the same parameters of respiration were obtained for comparison in PBMCs. We measured mitochondrial dynamics with microscopy with the same conditions. We enrolled 37 patients (17 in the CO group and 20 in the Control group for comparison) in the study. PMBCs obtained from subjects in the CO group had overall significantly lower respiration compared with the Control group (P < 0.0001). There was a significant increase in respiration with NV118, specifically with an increase in maximum respiration and respiration from complex II and complex IV (P < 0.0001). The mitochondria in PBMCs demonstrated an overall increase in net movement compared with the Control group. Our results of this study suggest that the therapeutic compound, NV118, increases respiration at complex II and IV as well as restoration of mitochondrial movement in PBMCs obtained from subjects with CO poisoning. Mitochondrial-directed therapy offers a potential future strategy with further exploration in vivo.The purpose of this study was to evaluate a new pharmacological strategy using a first-generation succinate prodrug, NV118, in peripheral blood mononuclear cells (PBMCs) obtained from subjects with carbon monoxide (CO) poisoning and healthy controls. We obtained human blood cells from subjects with CO poisoning and healthy control subjects. Intact PBMCs from subjects in the CO and Control group were analyzed with high-resolution respirometry measured in pmol O2 per second per 10-6 PBMCs. In addition to obtaining baseline respiration, NV118 (100 μM) was injected, and the same parameters of respiration were obtained for comparison in PBMCs. We measured mitochondrial dynamics with microscopy with the same conditions. We enrolled 37 patients (17 in the CO group and 20 in the Control group for comparison) in the study. PMBCs obtained from subjects in the CO group had overall significantly lower respiration compared with the Control group (P < 0.0001). There was a significant increase in respiration with NV118, specifically with an increase in maximum respiration and respiration from complex II and complex IV (P < 0.0001). The mitochondria in PBMCs demonstrated an overall increase in net movement compared with the Control group. Our results of this study suggest that the therapeutic compound, NV118, increases respiration at complex II and IV as well as restoration of mitochondrial movement in PBMCs obtained from subjects with CO poisoning. Mitochondrial-directed therapy offers a potential future strategy with further exploration in vivo. The purpose of this study was to evaluate a new pharmacological strategy using a first-generation succinate prodrug, NV118, in peripheral blood mononuclear cells (PBMCs) obtained from subjects with carbon monoxide (CO) poisoning and healthy controls. We obtained human blood cells from subjects with CO poisoning and healthy control subjects. Intact PBMCs from subjects in the CO and Control group were analyzed with high-resolution respirometry measured in pmol O 2 per second per 10 −6 PBMCs. In addition to obtaining baseline respiration, NV118 (100 μM) was injected, and the same parameters of respiration were obtained for comparison in PBMCs. We measured mitochondrial dynamics with microscopy with the same conditions. We enrolled 37 patients (17 in the CO group and 20 in the Control group for comparison) in the study. PMBCs obtained from subjects in the CO group had overall significantly lower respiration compared with the Control group ( P < 0.0001). There was a significant increase in respiration with NV118, specifically with an increase in maximum respiration and respiration from complex II and complex IV ( P < 0.0001). The mitochondria in PBMCs demonstrated an overall increase in net movement compared with the Control group. Our results of this study suggest that the therapeutic compound, NV118, increases respiration at complex II and IV as well as restoration of mitochondrial movement in PBMCs obtained from subjects with CO poisoning. Mitochondrial-directed therapy offers a potential future strategy with further exploration in vivo. |
| Author | Owiredu, Shawn Eckmann, David M. Shofer, Frances S. Jang, David H. Hardy, Kevin Kelly, Matthew Ranganathan, Abhay Lambert, David S. |
| Author_xml | – sequence: 1 givenname: Shawn surname: Owiredu fullname: Owiredu, Shawn organization: Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 2 givenname: Abhay surname: Ranganathan fullname: Ranganathan, Abhay organization: Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 3 givenname: David M. surname: Eckmann fullname: Eckmann, David M. organization: Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 4 givenname: Frances S. surname: Shofer fullname: Shofer, Frances S. organization: Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 5 givenname: Kevin surname: Hardy fullname: Hardy, Kevin organization: Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 6 givenname: David S. surname: Lambert fullname: Lambert, David S. organization: Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 7 givenname: Matthew surname: Kelly fullname: Kelly, Matthew organization: Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 8 givenname: David H. surname: Jang fullname: Jang, David H. organization: Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32374677$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UcluFDEQtVAQmQR-gAPykUsPXnrzBQlFYZEicYGz5TVx1O1qbPco-RG-F3cyQcCBU1l-m6reGTqJEB1CrynZU9qxd-p2MW6a9oR0XOwZoeIZ2lWANbTr-QnaEd7zpqctP0VnOd8SQlrWixfolDM-tP0w7NDPyzt8CAfAa3YYPN4Mm8Wl2Sk9OZxXY0JUxeElgU3rNValuLjWn4znUMDcQLQpqAnb--zXaEqAiEPEegKwD3YZgy4qRGexTzBjo5KunBki3AXrmgVChg0N0YZDsKua8kv03NfhXh3nOfr-8fLbxefm6uunLxcfrhrTElaazlLbaq85U51V1A3ctLRvqdaGKaIJ5_XRamucEqMehRdCUaEHSnrnfOv5OXr_6LusenaVF0tSk1xSmFW6l6CC_BuJ4UZew0HW842jYNXg7dEgwY_V5SLnkLetVXSwZsm4ECMfxcAr9c2fWb9DnsqohPGRYBLknJyXJhS1HbRGh0lSIrfe5bF3-dC73HqvUvaP9Mn9P6Jf6qK5pg |
| CitedBy_id | crossref_primary_10_35995_tmj20220202 crossref_primary_10_1016_j_chemosphere_2025_144213 crossref_primary_10_1016_j_lfs_2023_121880 crossref_primary_10_1080_15563650_2020_1870691 crossref_primary_10_3390_ijms222111786 crossref_primary_10_5937_scriptamed53_37038 crossref_primary_10_1016_j_lfs_2021_119616 crossref_primary_10_1016_j_cbi_2024_111266 crossref_primary_10_3389_fcell_2022_1010232 crossref_primary_10_1152_ajpcell_00022_2021 crossref_primary_10_1038_s41598_022_24472_3 crossref_primary_10_1007_s13181_020_00820_5 crossref_primary_10_1016_j_toxrep_2020_09_002 crossref_primary_10_3390_cells10092255 |
| Cites_doi | 10.1164/rccm.201207-1284CI 10.1111/j.1600-0773.1998.tb01425.x 10.22462/12.12.2016.1 10.1016/j.mito.2017.12.009 10.1080/15563650.2017.1288912 10.1042/BSR20150161 10.1097/SHK.0000000000001208 10.1093/brain/awx002 10.1038/labinvest.2013.53 10.1002/14651858.CD002041.pub2 10.1016/j.redox.2019.101165 10.1007/978-1-61779-382-0_3 10.1038/s41581-018-0004-8 10.2165/00139709-200524020-00002 10.1016/S0196-0644(95)70094-3 10.1016/j.bbamcr.2012.04.007 10.1186/1757-7241-19-16 10.1093/brain/aww303 10.1016/j.expneurol.2009.03.019 10.1016/j.nbd.2012.05.015 10.1007/978-1-4939-2257-4_22 10.1034/j.1600-0773.2003.930306.x 10.1371/journal.pone.0220490 10.1164/rccm.201606-1275CI 10.1042/CS20140101 10.1016/j.ajem.2017.08.048 10.1016/j.biocel.2014.05.019 10.1242/bio.029009 10.1186/s40635-018-0169-2 10.1016/S0196-0644(95)70261-X 10.1177/0885066616658449 10.22462/3.4.2017.1 10.1002/bit.25563 10.1152/jappl.1990.68.3.997 10.1038/ncomms12317 10.4103/2319-4170.155591 10.1172/jci.insight.128248 10.1006/taap.1993.1242 10.1017/S0266462305050208 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 the American Physiological Society 2020 American Physiological Society |
| Copyright_xml | – notice: Copyright © 2020 the American Physiological Society 2020 American Physiological Society |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1152/ajpcell.00539.2019 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Biology |
| DocumentTitleAlternate | EX VIVO USE OF CELL-PERMEABLE SUCCINATE |
| EISSN | 1522-1563 |
| EndPage | C135 |
| ExternalDocumentID | PMC7468892 32374677 10_1152_ajpcell_00539_2019 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIEHS NIH HHS grantid: R21ES031243 – fundername: NHLBI NIH HHS grantid: K08HL136858 – fundername: NHLBI NIH HHS grantid: R03HL154232 – fundername: ; grantid: R21ES031243 – fundername: ; grantid: K08HL136858; R03HL154232 |
| GroupedDBID | --- 23M 2WC 39C 4.4 53G 5GY 5VS 6J9 85S AAFWJ AAYXX ABJNI ACGFS ACPRK ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL BKKCC BKOMP BTFSW CITATION E3Z EBS EMOBN F5P GX1 H13 ITBOX KQ8 OK1 P2P PQQKQ RAP RHI RPL RPRKH TR2 W8F WH7 WOQ XSW YSK ~02 AIZTS DIK NPM RHF 7X8 5PM |
| ID | FETCH-LOGICAL-c402t-5d1d4bfb32a5da1e73c41641bbc2a0b033bc24bdcea98b89f99a19b7106eef4f3 |
| ISSN | 0363-6143 1522-1563 |
| IngestDate | Thu Aug 21 18:17:01 EDT 2025 Fri Jul 11 11:03:08 EDT 2025 Thu Jan 02 22:58:50 EST 2025 Thu Apr 24 23:09:15 EDT 2025 Tue Jul 01 01:08:16 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | carbon monoxide treatment succinate prodrug mitochondria |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c402t-5d1d4bfb32a5da1e73c41641bbc2a0b033bc24bdcea98b89f99a19b7106eef4f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://journals.physiology.org/doi/pdf/10.1152/ajpcell.00539.2019 |
| PMID | 32374677 |
| PQID | 2399838973 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7468892 proquest_miscellaneous_2399838973 pubmed_primary_32374677 crossref_citationtrail_10_1152_ajpcell_00539_2019 crossref_primary_10_1152_ajpcell_00539_2019 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-07-01 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Bethesda, MD |
| PublicationTitle | American Journal of Physiology: Cell Physiology |
| PublicationTitleAlternate | Am J Physiol Cell Physiol |
| PublicationYear | 2020 |
| Publisher | American Physiological Society |
| Publisher_xml | – name: American Physiological Society |
| References | B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B10 B32 B11 B33 B12 B34 B13 B35 B14 B36 B15 B37 B16 B17 B39 B18 B19 B1 B2 B3 B4 B5 B6 B7 B8 B9 Weaver LK (B38) 2016; 43 |
| References_xml | – ident: B11 doi: 10.1164/rccm.201207-1284CI – ident: B25 doi: 10.1111/j.1600-0773.1998.tb01425.x – volume: 43 start-page: 747 year: 2016 ident: B38 publication-title: Undersea Hyperb Med doi: 10.22462/12.12.2016.1 – ident: B13 doi: 10.1016/j.mito.2017.12.009 – ident: B15 doi: 10.1080/15563650.2017.1288912 – ident: B21 doi: 10.1042/BSR20150161 – ident: B17 doi: 10.1097/SHK.0000000000001208 – ident: B2 doi: 10.1093/brain/awx002 – ident: B6 doi: 10.1038/labinvest.2013.53 – ident: B19 doi: 10.1002/14651858.CD002041.pub2 – ident: B7 doi: 10.1016/j.redox.2019.101165 – ident: B28 doi: 10.1007/978-1-61779-382-0_3 – ident: B12 doi: 10.1038/s41581-018-0004-8 – ident: B4 doi: 10.2165/00139709-200524020-00002 – ident: B39 doi: 10.1016/S0196-0644(95)70094-3 – ident: B24 doi: 10.1016/j.bbamcr.2012.04.007 – ident: B27 doi: 10.1186/1757-7241-19-16 – ident: B8 doi: 10.1093/brain/aww303 – ident: B36 doi: 10.1016/j.expneurol.2009.03.019 – ident: B35 doi: 10.1016/j.nbd.2012.05.015 – ident: B23 doi: 10.1007/978-1-4939-2257-4_22 – ident: B1 doi: 10.1034/j.1600-0773.2003.930306.x – ident: B26 doi: 10.1371/journal.pone.0220490 – ident: B31 doi: 10.1164/rccm.201606-1275CI – ident: B5 doi: 10.1042/CS20140101 – ident: B29 doi: 10.1016/j.ajem.2017.08.048 – ident: B30 doi: 10.1016/j.biocel.2014.05.019 – ident: B18 doi: 10.1242/bio.029009 – ident: B16 doi: 10.1186/s40635-018-0169-2 – ident: B34 doi: 10.1016/S0196-0644(95)70261-X – ident: B14 doi: 10.1177/0885066616658449 – ident: B10 doi: 10.22462/3.4.2017.1 – ident: B20 doi: 10.1002/bit.25563 – ident: B32 doi: 10.1152/jappl.1990.68.3.997 – ident: B9 doi: 10.1038/ncomms12317 – ident: B22 doi: 10.4103/2319-4170.155591 – ident: B3 doi: 10.1172/jci.insight.128248 – ident: B33 doi: 10.1006/taap.1993.1242 – ident: B37 doi: 10.1017/S0266462305050208 |
| SSID | ssj0004269 |
| Score | 2.3928785 |
| Snippet | The purpose of this study was to evaluate a new pharmacological strategy using a first-generation succinate prodrug, NV118, in peripheral blood mononuclear... The purpose of this study was to evaluate a new pharmacological strategy using a first generation succinate prodrug, NV118, in peripheral blood mononuclear... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | C129 |
| Title | Ex vivo use of cell-permeable succinate prodrug attenuates mitochondrial dysfunction in blood cells obtained from carbon monoxide-poisoned individuals |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32374677 https://www.proquest.com/docview/2399838973 https://pubmed.ncbi.nlm.nih.gov/PMC7468892 |
| Volume | 319 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiQuCFoe4aVFQlwsh9hrJ-tjFAVVoCIhWqk3a9e7blKIHcVxSfgh_FB-ATPrdwOIcrGctT22dz7PzkzmQcjriHvK58PYVmwU257PY1uMXGEPhZQsiBlXApOTTz6Ojs-89-f-ea_3sxW1lG_kIPr-27yS_-EqjAFfMUv2BpyticIA7AN_YQschu0_8Xi2ta4WV6mVFw55dMLbKxC12uRDZXkULRLQJTEIS63zCwtraSY5apfWEr5kkHyJMl071C7DBa4KfDTR7IZcZqUSnQeglppElEisJZwDb5huF0rbqxSjkTQWcKoSu7K2vlv_IdRSfE3QaZEkwybW1DgP66Ha6Ys1lFVunLNz8a3JVxPJhSgc_kasyXkTBTSLvizLns8mVN86GdQOpHkaF-A0nURgAj4P2g4PsG6r4Ngm0YuBxVtUdxroUm6DTQ2mKGsLdlYK4zaCCzE9dUo3iy5_FiVT9pcTH8vTissVzvgABRbmNpVkO7W7r62pdaSjsbF8NyxphIZGiDRukdsumDbYdePDp1aFe9e0Yaxfskr08t23-8_RVab2LKTrgb4tzen0PrlXcp5OCvw-ID2dHJKjCTAxXe7oG9ow_5DcKXqj7o7Ij9mWIrgpgJumMe2Cm9bgpiW4aQNu2gE3bYGbLhJqwG3IZbQCN0Vw0wLcdA_ctAXuh-Ts3ex0emyXTUTsyBu6G9tXjvJkLJkrfCUcPWYR2CCeI2XkiqEcMgY7noQpEgGXPIiDQDiBBMV7pHXsxewROUjgXk8I9f1RgN0MpIp9DxZGrl09xhiIWPPAk7xPnIobYVRW2MdGL1_DP6OgT6z6mlVRX-avZ7-qmBzCMoBHRaLTPAsxRZ2D8TFmffK4YHpNj7kMmwqN-2TcgUN9ApaY7x5JFnNTah6u4zxwn97oKZ-Ru813-5wcbNa5fgGq-0a-NFj_BUOZ-58 |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ex+vivo+use+of+cell-permeable+succinate+prodrug+attenuates+mitochondrial+dysfunction+in+blood+cells+obtained+from+carbon+monoxide-poisoned+individuals&rft.jtitle=American+Journal+of+Physiology%3A+Cell+Physiology&rft.au=Owiredu%2C+Shawn&rft.au=Ranganathan%2C+Abhay&rft.au=Eckmann%2C+David+M.&rft.au=Shofer%2C+Frances+S.&rft.date=2020-07-01&rft.issn=0363-6143&rft.eissn=1522-1563&rft.volume=319&rft.issue=1&rft.spage=C129&rft.epage=C135&rft_id=info:doi/10.1152%2Fajpcell.00539.2019&rft.externalDBID=n%2Fa&rft.externalDocID=10_1152_ajpcell_00539_2019 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0363-6143&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0363-6143&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0363-6143&client=summon |